

REMARKS

The pending claims are claims 13, 14, and 17-25 as amended on July 20, 2004. These claims have been limited to the use of alpha 2 selective agonists to overcome the Examiner's objection under 35 USC 112 that the term "neuroprotectant compound" was in violation of the 35 USC 112 requirement for a "written description".

As discussed at the USPTO on April 13, 2005, the claims as limited to the use of alpha 2 selective agonists is not properly rejected under 35 USC 112 for written description. (The Examiner's suggestion of lack of enablement was discussed in Applicant's amendment of July 20, 2004. This discussion is relied on to show that any rejection under 35 USC 112 for lack of enablement is incorrect.)

It is requested that the Examiner reconsider and withdraw the outstanding rejection.

Respectfully submitted,

*RJ Baran*  
Robert J. Baran  
Registration No. 25,806  
Attorney of Record  
ALLERGAN, INC. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612  
Telephone: 714/246-4669  
Telecopier: 714/246-4249

CERTIFICATE OF MAILING  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: MAIL STOP REPLY-NON-FEE, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 ON 4/21/05 PRINTED NAME OF PERSON MAKING DEPOSIT: BONNIE FERGUSON  
SIGNATURE OF PERSON MAKING DEPOSIT: *Bonnie Ferguson* Date: 4/21/05